165 related articles for article (PubMed ID: 6326517)
1. Cyclic nucleotide derivatives as probes of phosphodiesterase catalytic and regulatory sites.
Erneux C; Couchie D; Dumont JE; Jastorff B
Adv Cyclic Nucleotide Protein Phosphorylation Res; 1984; 16():107-18. PubMed ID: 6326517
[TBL] [Abstract][Full Text] [Related]
2. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the soluble fraction of the human brain: Kinetic properties and the effect of the antidepressant pyrazidol and its nitro analog on the enzyme].
Medvedeva MV; Belov AA; Kireeva NN; Bobruskin ID
Biokhimiia; 1993 May; 58(5):798-808. PubMed ID: 8393348
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948.
Gillespie PG; Beavo JA
Mol Pharmacol; 1989 Nov; 36(5):773-81. PubMed ID: 2555675
[TBL] [Abstract][Full Text] [Related]
4. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
[TBL] [Abstract][Full Text] [Related]
5. [Kinetic properties and regulation of cyclic nucleotide phosphodiesterases in lymphoid cells].
Azhaeva EV; Severin ES
Bioorg Khim; 1987 Sep; 13(9):1157-63. PubMed ID: 2827690
[TBL] [Abstract][Full Text] [Related]
6. The role of phosphodiesterase isoforms 2, 5, and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord.
de Vente J; Markerink-van Ittersum M; Vles JS
J Chem Neuroanat; 2006 Jun; 31(4):275-303. PubMed ID: 16621445
[TBL] [Abstract][Full Text] [Related]
7. A comparative kinetic study of bovine calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes utilizing cAMP, cGMP and their 2'-O-anthraniloyl-,2'-O-(N-methylanthraniloyl)-derivatives as substrates.
Grewal J; Karuppiah N; Mutus B
Biochem Int; 1989 Dec; 19(6):1287-95. PubMed ID: 2561449
[TBL] [Abstract][Full Text] [Related]
8. Regulation of multiple forms of cyclic nucleotide phosphodiesterase from bovine hypothalamus: new factors modulating enzyme activity.
Galoyan AA; Gurvitz BYa
Neurochem Res; 1985 Nov; 10(11):1467-81. PubMed ID: 3003614
[TBL] [Abstract][Full Text] [Related]
9. Equilibrium kinetics model for the cGMP-stimulated phosphodiesterase of brain coated vesicles.
Silva WI; Puszkin S
Bol Asoc Med P R; 1990 Sep; 82(9):407-11. PubMed ID: 1963777
[TBL] [Abstract][Full Text] [Related]
10. Differential susceptibility to biological detergents of the particulate cGMP-stimulated phosphodiesterase from rat heart: preservation of the allosteric properties of the solubilized enzyme.
Timouyasse L; Prigent AF; Némoz G; Lagarde M; Pachéco H
Biochem Int; 1989 Aug; 19(2):287-99. PubMed ID: 2554908
[TBL] [Abstract][Full Text] [Related]
11. [cGMP-activated phosphodiesterase from human brain: kinetic and regulatory properties].
Bobruskin ID; Medvedeva MV; Severin ES
Biokhimiia; 1991 Jun; 56(6):999-1010. PubMed ID: 1657216
[TBL] [Abstract][Full Text] [Related]
12. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins.
Butt E; Beltman J; Becker DE; Jensen GS; Rybalkin SD; Jastorff B; Beavo JA
Mol Pharmacol; 1995 Feb; 47(2):340-7. PubMed ID: 7870042
[TBL] [Abstract][Full Text] [Related]
13. [The process of cyclic adenosine-3',5'-monophosphate phosphodiesterase activation by 2',5'-oligoadenylate].
Tunitskaia VL; Itkes AV; Kochetkova MN; Severin ES
Biokhimiia; 1983 Oct; 48(10):1721-5. PubMed ID: 6315087
[TBL] [Abstract][Full Text] [Related]
14. Specific effects of n-3 fatty acids and 8-bromo-cGMP on the cyclic nucleotide phosphodiesterase activity in neonatal rat cardiac myocytes.
Picq M; Dubois M; Grynberg A; Lagarde M; Prigent AF
J Mol Cell Cardiol; 1996 Oct; 28(10):2151-61. PubMed ID: 8930810
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of deletion recombinants of two cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE-3).
He R; Komas N; Ekholm D; Murata T; Taira M; Hockman S; Degerman E; Manganiello VC
Cell Biochem Biophys; 1998; 29(1-2):89-111. PubMed ID: 9631240
[TBL] [Abstract][Full Text] [Related]
17. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
18. Cyclic nucleotide-mediated regulation of vascular smooth muscle cell cyclic nucleotide phosphodiesterase activity. Selective effect of cyclic AMP.
Maurice DH
Cell Biochem Biophys; 1998; 29(1-2):35-47. PubMed ID: 9631237
[TBL] [Abstract][Full Text] [Related]
19. Activation of cyclic GMP-binding and cyclic AMP-specific phosphodiesterases of rat platelets by a mechanism involving cyclic AMP-dependent phosphorylation.
Tremblay J; Lachance B; Hamet P
J Cyclic Nucleotide Protein Phosphor Res; 1985; 10(4):397-411. PubMed ID: 2411769
[TBL] [Abstract][Full Text] [Related]
20. "cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
Bellamy TC; Garthwaite J
Mol Pharmacol; 2001 Jan; 59(1):54-61. PubMed ID: 11125024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
